Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
SERPASIL-ESIDRIX #1 vs ALDORIL D30
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Reserpine depletes catecholamines (norepinephrine, dopamine) from central and peripheral nerve endings by irreversibly inhibiting the vesicular monoamine transporter (VMAT2), leading to reduced sympathetic outflow and vasodilation. Hydrochlorothiazide inhibits the Na+-Cl- symporter in the distal convoluted tubule, reducing sodium and water reabsorption.
Aldoril D30 is a combination of methyldopa, a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow, and hydrochlorothiazide, a thiazide diuretic that inhibits the sodium-chloride symporter in the distal convoluted tubule, decreasing plasma volume and peripheral resistance.
Hypertension
Hypertension
1 tablet orally twice daily, titrate to response. Each tablet contains reserpine 0.1 mg and hydrochlorothiazide 25 mg.
Oral: 1 tablet (hydrochlorothiazide 30 mg / methyldopa 500 mg) twice daily; maximum dose: 2 tablets twice daily.
Reserpine: 50-100 hours (terminal); clinical effects persist due to irreversible adrenergic neuron blockade. Hydrochlorothiazide: 6-15 hours (terminal).
Terminal elimination half-life of hydrochlorothiazide is 6-15 hours; methyldopa half-life is 1.8 hours (normal renal function). In renal impairment, half-life of both components is prolonged.
Reserpine: extensive hepatic metabolism; Hydrochlorothiazide: not significantly metabolized, excreted unchanged in urine.
Methyldopa is metabolized by conjugation (catechol-O-methyltransferase) and hepatic sulfation; hydrochlorothiazide is not extensively metabolized and is excreted unchanged by the kidney.
Reserpine: renal (30% as metabolites, <1% unchanged), fecal (60% as metabolites). Hydrochlorothiazide: renal (>95% unchanged).
Renal: approximately 50% as parent drug and metabolites; biliary/fecal: minimal, less than 5%.
Reserpine: 96% bound to albumin. Hydrochlorothiazide: 68% bound to plasma proteins.
Methyldopa: <10% bound to plasma proteins; hydrochlorothiazide: 40-68% bound to albumin.
Reserpine: 6-8 L/kg (extensive tissue binding, especially adrenergic neurons). Hydrochlorothiazide: 0.8-1.0 L/kg (enters erythrocytes).
Methyldopa: Vd 0.2-0.3 L/kg (distributes into tissues, crosses placenta); hydrochlorothiazide: Vd 0.75-1.5 L/kg (extensively distributed, does not cross blood-brain barrier significantly).
Reserpine: oral 30-50% (presystemic metabolism). Hydrochlorothiazide: oral 65-75%.
Oral bioavailability of methyldopa is approximately 25% (variable, influenced by gut metabolism); hydrochlorothiazide bioavailability is 65-75%.
e GFR 30-50 m L/min: reduce dose by 50% or extend interval. e GFR <30 m L/min: contraindicated due to thiazide ineffectiveness.
GFR 30-60 m L/min: reduce dose by 50%; GFR <30 m L/min: not recommended.
Child-Pugh A: standard dosing. Child-Pugh B: reduce reserpine dose by 50%. Child-Pugh C: avoid use.
Child-Pugh Class B or C: contraindicated; use not recommended.
Reserpine: 0.005-0.02 mg/kg/day orally in 1-2 divided doses. Hydrochlorothiazide: 1-2 mg/kg/day orally in 2 divided doses. Adjust per response.
Not recommended for use in pediatric patients due to lack of safety and efficacy data.
Start at half the standard dose (0.5 tablet orally daily). Titrate slowly due to increased sensitivity to hypotension, CNS depression, and electrolyte disturbances.
Start with lowest dose; monitor for hypotension, electrolyte imbalance, and CNS effects; consider reduced initial dose.
None
None
May cause mental depression, including suicidal risk,Electrolyte imbalances (hypokalemia, hyponatremia, hypomagnesemia),Orthostatic hypotension,Increased risk of arrhythmias with digoxin,May exacerbate systemic lupus erythematosus,May activate peptic ulcer,Monitor renal function and electrolytes
May cause hemolytic anemia, liver disorders, positive Coombs test, sedation, depression, and hypersensitivity reactions. Hydrochlorothiazide may cause electrolyte imbalance, hyperuricemia, photosensitivity, and exacerbation of systemic lupus erythematosus. Use with caution in renal impairment, hepatic disease, and in patients with a history of drug-induced hemolytic anemia.
History of mental depression or suicidal thoughts,Active peptic ulcer,Ulcerative colitis,Electroconvulsive therapy (ECT) within 2 weeks,Anuria,Hypersensitivity to reserpine, hydrochlorothiazide, or sulfonamides
Active hepatic disease, history of previous methyldopa therapy-associated liver disorders; anuria; hypersensitivity to methyldopa, hydrochlorothiazide, or sulfonamide-derived drugs.
Avoid high-potassium foods (bananas, oranges, leafy greens) if taking potassium-sparing agents, but this combination does not include them. Limit sodium intake to enhance antihypertensive effect. Avoid grapefruit juice as it may increase reserpine absorption. Maintain adequate fluid intake but avoid excessive water intake due to risk of hyponatremia.
Food may decrease absorption of methyldopa. Avoid excessive intake of high-potassium foods (e.g., bananas, oranges) unless directed. Hydrochlorothiazide may cause potassium depletion; maintain adequate dietary potassium. Avoid natural licorice as it can worsen hypokalemia.
First trimester: Reserpine crosses placenta; associated with increased risk of congenital malformations (neural tube defects, cardiovascular anomalies) based on animal data and limited human reports. Second/third trimester: Use associated with fetal bradycardia, hypotonia, hypothermia, respiratory depression, and meconium ileus due to catecholamine depletion; risk of neonatal hypotension and poor feeding. Avoid in pregnancy unless benefit outweighs risk.
First trimester: Limited data; no clear evidence of major malformations but methyldopa crosses placenta. Second and third trimesters: Associated with reduced placental perfusion; possible fetal bradycardia and neonatal hypotension. Hydrochlorothiazide may cause fetal/neonatal jaundice, thrombocytopenia, and electrolyte disturbances.
Reserpine excreted in breast milk; M/P ratio not established. Concentrations may be low but can cause infant respiratory depression, nasal congestion, and cyanosis. Hydrochlorothiazide also excreted; may suppress lactation. Contraindicated during breastfeeding.
Methyldopa is excreted in breast milk in low concentrations; M/P ratio approximately 0.2. Hydrochlorothiazide is excreted in minimal amounts; may suppress lactation. Consider risks versus benefits.
No established safe dose; if unavoidable, use lowest effective dose. Pregnancy-induced hemodilution and increased renal clearance may reduce drug levels; however, due to toxicity, dose adjustment not recommended. Consider alternative antihypertensives (e.g., labetalol, nifedipine).
Methyldopa: Pregnancy-induced plasma volume expansion may require dose titration; monitor blood pressure and adjust accordingly. Hydrochlorothiazide: Often avoided in pregnancy due to volume depletion risks; if used, monitor electrolytes and renal function, no pharmacokinetic data necessitate routine dose adjustment.
Serpasil-Esidrix #1 combines reserpine (a Rauwolfia alkaloid) and hydrochlorothiazide (a thiazide diuretic). Reserpine depletes catecholamines and serotonin, causing gradual BP reduction. Onset of antihypertensive effect is delayed (2-3 weeks). Monitor for depression, nasal congestion, and extrapyramidal effects. Hydrochlorothiazide may cause hypokalemia, hyponatremia, and hyperglycemia. Avoid use in patients with history of depression, peptic ulcer, or electrolyte imbalances. Combination product offers convenience but fixed dosing limits titration.
ALDORIL D30 combines methyldopa (central alpha-2 agonist) and hydrochlorothiazide (thiazide diuretic). Monitor for orthostatic hypotension, especially at initiation. Taper not needed for methyldopa but discontinue if fever or liver dysfunction occurs. Interferes with urinary catecholamine measurements (false elevation). Hydrochlorothiazide may cause hyponatremia, hypokalemia, and hyperglycemia; check electrolytes and glucose periodically.
Take this medication exactly as prescribed, usually once daily in the morning to avoid nighttime urination.,Do not stop abruptly; sudden withdrawal may cause rapid blood pressure rise.,Report symptoms of depression, mood changes, or unusual tiredness promptly.,Avoid alcohol, which may increase dizziness and drowsiness.,Use sun protection; this drug increases photosensitivity risk.,Monitor for signs of electrolyte imbalance: muscle cramps, weakness, irregular heartbeat.,Weigh yourself regularly and report rapid weight gain or swelling.,Avoid potassium supplements or salt substitutes unless directed by your doctor.
Take exactly as prescribed, preferably with food to reduce stomach upset.,Rise slowly from sitting or lying down to prevent dizziness.,This drug may make you drowsy; avoid driving or operating machinery until you know how it affects you.,Report fever, unexplained fatigue, jaundice, or dark urine immediately.,Weigh yourself daily and report rapid weight gain or swelling.,Limit alcohol intake as it can increase side effects.,Do not use salt substitutes containing potassium without consulting your doctor.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about SERPASIL-ESIDRIX #1 vs ALDORIL D30, answered by our medical review team.
SERPASIL-ESIDRIX #1 is a Antihypertensive Combination that works by Reserpine depletes catecholamines (norepinephrine, dopamine) from central and peripheral nerve endings by irreversibly inhibiting the vesicular monoamine transporter (VMAT2), leading to reduced sympathetic outflow and vasodilation. Hydrochlorothiazide inhibits the Na+-Cl- symporter in the distal convoluted tubule, reducing sodium and water reabsorption.. ALDORIL D30 is a Antihypertensive Combination that works by Aldoril D30 is a combination of methyldopa, a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow, and hydrochlorothiazide, a thiazide diuretic that inhibits the sodium-chloride symporter in the distal convoluted tubule, decreasing plasma volume and peripheral resistance.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between SERPASIL-ESIDRIX #1 and ALDORIL D30 depend on the specific clinical indication. These are both Antihypertensive Combination agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of SERPASIL-ESIDRIX #1 is: 1 tablet orally twice daily, titrate to response. Each tablet contains reserpine 0.1 mg and hydrochlorothiazide 25 mg.. The standard adult dose of ALDORIL D30 is: Oral: 1 tablet (hydrochlorothiazide 30 mg / methyldopa 500 mg) twice daily; maximum dose: 2 tablets twice daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between SERPASIL-ESIDRIX #1 and ALDORIL D30 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. SERPASIL-ESIDRIX #1 is classified as Category C. First trimester: Reserpine crosses placenta; associated with increased risk of congenital malformations (neural tube defects, cardiovascular anomalies) based on animal data and lim. ALDORIL D30 is classified as Category C. First trimester: Limited data; no clear evidence of major malformations but methyldopa crosses placenta. Second and third trimesters: Associated with reduced placental perfusion; p. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.